Abstract：
:We described the clinical features and outcomes for 63 adult patients with acute myeloid leukemia (AML) with a translocation involving the 11q23 locus (MLL) who were treated at Memorial Sloan Kettering Cancer Center (MSK). The population included 40 female (63 %) and 23 male (37 %) patients, with a median age of 51 years old (range 18-82 years). Of the 31 patients who had had an antecedent malignancy, 14 (45 %) had had breast cancer or DCIS and 22 (71 %) had received anthracycline-based systemic chemotherapy. The translocation partner for the 11q23 rearrangement was identified in 60 of the 63 patients (95 %) studied. The distribution of translocation partners differed for those who had previously received cytotoxic chemotherapy. Most patients with therapy-related disease had a 9p22 or 19p13 partner, as compared to those with de novo disease (95 % vs. 68 %, p = 0.023). Of the 30 patients who received all therapy under observation, 15 (50 %) patients had de novo disease and 15 (50 %) had received antecedent chemotherapy. No significant difference in survival was observed between groups (p = 0.44). Twenty-two patients received induction as up-front therapy, of whom 11 (50 %) achieved CR / CRi. The achievement of CR / CRi with one course of induction was associated with improved OS, with a 6-month OS of 73 % as compared to 23 % for those who did not (p = 0.018). The achievement of CR / CRi with a single course of induction may be a marker of favorable survival in this subtype of high-risk AML. KEY POINT: Response to a single induction was associated with favorable survival in this population.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Menghrajani K,Zhang Y,Famulare C,Devlin SM,Tallman MSdoi
10.1016/j.leukres.2020.106453subject
Has Abstractpub_date
2020-11-01 00:00:00pages
106453eissn
0145-2126issn
1873-5835pii
S0145-2126(20)30158-2journal_volume
98pub_type
杂志文章abstract：:We examined polymorphisms of glutathione S-transferase (GST) genes in 159 Japanese patients with myelodysplasia and compared the incidence with that in 43 normal individuals to clarify their pathogenetic significance in myelodysplasia. In individuals with the GSTT1 null genotype, the odds ratios for disease risk were ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(99)00119-8
更新日期：1999-11-01 00:00:00
abstract：:Multiple myeloma patients may develop extraosseous involvement in the course of the disease making prognosis very poor and new drugs clearly needed. The PD-1/PD-L1 axis has emerged as a master immune checkpoint in antitumor responses and recent studies investigated the role of PD-L1 in multiple myeloma cells; no data ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2016.09.008
更新日期：2016-10-01 00:00:00
abstract：:A panel of human leukemia cell lines from various lineages (T-cell, pre B- and Non-T/Non-B cell, myelomonocytic and erythroleukemia cell lines) were utilised as model systems of the distant effects of differentiation-inducing activity (DIA) produced by the T-leukemia cell line HUT-102. DIA inhibited cell proliferation...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(87)90108-1
更新日期：1987-01-01 00:00:00
abstract：OBJECTIVE:Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients. We report here our results tes...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2009.04.006
更新日期：2009-12-01 00:00:00
abstract：BACKGROUND:The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting from the JAK2 V617F mutation. LY2784544 (gandotinib) is a potent, selective, small-molecule inhibitor of JAK2 that has potential dose-dependent selectivit...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2018.06.014
更新日期：2018-08-01 00:00:00
abstract：:There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2020.106385
更新日期：2020-08-01 00:00:00
abstract：:We employed a liquid culture system to examine the in vitro effects of vincristine and vindesine on cellular incorporation of 35SO4 into leukemic cells obtained from 5 patients with chronic granulocytic leukemia in blast crisis. The per cent of 35SO4 into drug-treated as compared to saline-treated leukemic cells was c...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(84)90062-6
更新日期：1984-01-01 00:00:00
abstract：:Osteogenic growth peptide (OGP) is a peptide exerting regulatory effects on the bone and on bone marrow. The carboxy-terminal pentapeptide (OGP10-14) is the biologically active portion of OGP. We evaluated OGP10-14 hematopoietic activity performing colony-forming tests on human stem cells derived by bone marrow, perip...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(02)00008-5
更新日期：2002-09-01 00:00:00
abstract：:As a part of our continuing efforts to develop gene therapy for acute myelogenous leukemia (AML), this study was undertaken to evaluate the possibility of using autologous bone marrow stromal fibroblasts (BMSFs) as a target cell population. Autologous BMSFs in AML were isolated from the stromal layers of long-term bon...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(01)00134-5
更新日期：2002-04-01 00:00:00
abstract：:The oral bacterium, Aggregatibacter actinomycetemcomitans, produces a leukotoxin (LtxA) that is specific for white blood cells (WBCs) from humans and Old World primates by interacting with lymphocyte function antigen-1 (LFA-1) on susceptible cells. To determine if LtxA could be used as a therapeutic agent for the trea...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2009.08.022
更新日期：2010-06-01 00:00:00
abstract：:In a recent phase I study, a combination of gemcitabine at 10 mg/(m(2)min) for 12 h and mitoxantrone 12 mg/m(2) daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refrac...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/s0145-2126(02)00171-6
更新日期：2003-04-01 00:00:00
abstract：:Multiple myeloma (MM) is an incurable plasma cell malignancy, which causes a significant morbidity due to organ damage and bone tissue destruction. In recent years, novel drugs have become available for MM therapy thanks to a more deepened knowledge of this disease's pathogenesis. The perspective of employing targeted...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/j.leukres.2012.10.016
更新日期：2013-02-01 00:00:00
abstract：:The tumor microenvironment (TME) is critical to the longevity of tumor B cells in chronic lymphocytic leukemia (CLL). Bone marrow mesenchymal stem cells (BMMSCs) and the cytokines they produce including IL-6 are important components of the TME in CLL. We found BMMSCs supported the survival of CLL cells in vitro throug...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2018.01.006
更新日期：2018-03-01 00:00:00
abstract：:We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed sporadic Burkitt lymphoma. BLUE-1 carries the pathognomonic t(8;14)(q24;q32) effecting MYC/IgHJ fusion and a novel t(6;20)(...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.03.026
更新日期：2006-11-01 00:00:00
abstract：:It has been suggested that acidic isoferritins play a major role in the regulation of human granulocyte-macrophage (CFU-GM) proliferation. Such regulatory isoferritins are said to occur in some human tissues including both leukaemic and normal leucocytes, and certain established cell lines. They are glycosylated and b...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(84)90065-1
更新日期：1984-01-01 00:00:00
abstract：:Preclinical data suggest that all-trans retinoic acid (ATRA) synergizing with granulocyte colony stimulating factor (G-CSF), can improve the effectiveness of chemotherapy in acute myeloid leukemia (AML). Fludarabine 15 mg/m(2) is the minimum dose able to optimize intensification with fludarabine-arabinosylcytosine reg...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2008.12.014
更新日期：2009-08-01 00:00:00
abstract：:During monocyte-macrophage differentiation of HL-60 cells by 12-O-tetradecanoyl phorbol 13-acetate, the intracellular globular(G)-actin and polymerized(F)-actin increased 3-fold and 1.7-fold, respectively. Time course studies showed that these changes of actin levels were nearly coincident with the development of macr...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(89)90121-5
更新日期：1989-01-01 00:00:00
abstract：BACKGROUND:Chromosomal aberrations at the ETV6 gene locus on 12p13.2 are common in bone marrow samples involved by blastic plasmacytoid dendritic cell neoplasm (BPDCN). However, their pathogenic role, incidence in cutaneous BPDCN lesions, and clinical significance have not been assessed systematically. RESULTS:The stu...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2018.09.006
更新日期：2018-10-01 00:00:00
abstract：:This study aimed at optimizing the conditions for flow cytometric detection of myeloperoxidase (MPO), cytoplasmic CD3 (cCD3), and cytoplasmic CD22 (cCD22), which seem to be more reliable lineage-associated markers in acute leukemia than surface antigens. Fixation methods employing saponin as detergent resulted in accu...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(93)90102-q
更新日期：1993-05-01 00:00:00
abstract：:Overexpression of the Wilms' tumor gene 1 (WT1) was observed in most leukemia cells. In addition to four major isoforms of WT1, an N-terminally truncated isoforms (sWT1) has been identified. We separately quantified the transcript levels of sWT1 and full-length WT1 (fWT1) in 237 patients with acute myeloid leukemia (A...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.01.002
更新日期：2011-05-01 00:00:00
abstract：:The purpose of this study was to determine the sensitivity to merocyanine 540 (MC 540)-mediated photolysis of normal human hematopoietic progenitor cells and four leukemia cell lines (Daudi, Raji, K562 and HL-60). Late erythroid progenitors were the most sensitive normal cells. Early erythroid progenitors were of inte...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(87)90104-4
更新日期：1987-01-01 00:00:00
abstract：:Hematopoiesis is regulated by several cytokines with pleiotropic activity. Several evidences have clearly demonstrated that these molecules, formerly regarded as specific for the hematopoietic system, also affect certain endothelial cell functions and that hematopoietic factors clearly influence angiogenesis. This rev...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/j.leukres.2012.02.003
更新日期：2012-05-01 00:00:00
abstract：:Despite the high effectiveness of various P-glycoprotein (P-gp) modulating substances in vitro their clinical value e.g. for combination treatment of acute myelogenous leukemias (AML) remains still unclear. This might be explainable by recent findings that other factors than P-gp (e.g. the multidrug resistance associa...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(98)00192-1
更新日期：1999-05-01 00:00:00
abstract：BACKGROUND:Growing evidence demonstrates that an increased number of CD68 positive tumor-associated macrophages (TAM) is associated with decreased survival in patients with newly diagnosed classic Hodgkin lymphoma (HL). However, the impact of TAM in relapsed and refractory disease is unknown. DESIGN AND METHODS:To inv...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2013.03.021
更新日期：2013-09-01 00:00:00
abstract：:The prognostic impact of combined NPM1+/FLT3- genotype is not well defined in elderly patients with acute myeloid leukemia (AML), and in the setting of different treatments, such as cytotoxic chemotherapy (Chemo), hematopoietic cell transplantation (HCT), or hypomethylating agents (HMA). Eighty-two elderly (age >60 ye...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2015.09.001
更新日期：2015-09-03 00:00:00
abstract：:miRNAs have been reported to be involved in the pathogenesis of many cancers. In this article, we investigated the role and the mechanisms of miR-15a/16 in the pathogenesis of multiple myeloma (MM). We found that miR-15a/16 was down-regulated in bone marrow-derived mononuclear cells (BM-MNCs) of newly diagnosed patien...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2016.08.013
更新日期：2016-10-01 00:00:00
abstract：BACKGROUND:Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of iron overload and associated organ damage, and death. Emerging evidence indicates that iron chelation therapy (ICT) could reduce mortality and improve survival in transfusion-dependent MDS patients, especially those classi...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2014.02.003
更新日期：2014-05-01 00:00:00
abstract：:Thirteen hairy-cell leukaemia patients were treated with IFN-beta (6 X 10(6) IU/m2) for 7 days, alternate weeks, for three cycles. IFN-beta was then continued at the same dose twice a week for 24 weeks. Treatment was discontinued in 2 non-responders and 2 partial responders (1 haem PR, 1 path PR) because of complicati...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(90)90071-g
更新日期：1990-01-01 00:00:00
abstract：:Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the in...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2012.07.015
更新日期：2012-11-01 00:00:00
abstract：:Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We st...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2009.07.022
更新日期：2010-04-01 00:00:00
